7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

1/5
Please reload

Featured Posts

Cytox Bolsters Support Through Stake By Masa Life Science Ventures

April 6, 2009

Birmingham, United Kingdom - Alzheimer's disease diagnostic developer Cytox Ltd, has raised an undisclosed amount of funding through Masa Life Science Ventures in an ongoing fund-raising, VentureWire has learned.

 

Cytox Chief Executive and Director Richard Hadden declined to provide more details.

 

Cytox, founded in 2004, was initially incubated at and licensed its technology from the University of Oxford. The company's technology is designed to detect biomarkers associated with the cell division of brain cells to determine whether symptoms experienced by potential clinical-trial patients are symptoms of aging or early Alzheimer's disease.

 

Cytox raised this most recent funding around late last year or early this year, Hadden said. The company previously raised GBP1.2 million in 2006 including Birmingham, U.K.-based venture investor MidVen. MidVen is Cytox's largest investor, Hadden said, after investing GBP500,000. The company also has secured GBP400,000 in regional grant funding through Advantage West Midlands.

 

Separately, Masa founder and Managing Partner Sinclair Dunlop said his firm last summer added Director Kyp Sirinakis to fill a new position on the investment management team. Sirinakis previously was managing director at WomenAngels.net and director of the technology resource alliance at George Mason University Entrepreneurship Center.

 

http://www.cytoxgroup.com

 

http://www.mlsvfund.com

 

Please reload

NEWS